Philips S. Schein
#126,828
Most Influential Person Now
Philips S. Schein's AcademicInfluence.com Rankings
Philips S. Scheinmedical Degrees
Medical
#2033
World Rank
#2427
Historical Rank
Dermatology
#32
World Rank
#45
Historical Rank
Download Badge
Medical
Why Is Philips S. Schein Influential?
(Suggest an Edit or Addition)Philips S. Schein's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Cutaneous T-cell lymphomas: the Sézary syndrome, mycosis fungoides, and related disorders. (1975) (609)
- ADVANCED DIFFUSE HISTIOCYTIC LYMPHOMA, A POTENTIALLY CURABLE DISEASE RESULTS WITH COMBINATION CHEMOTHERAPY (1975) (476)
- Bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma. (1976) (354)
- 5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer. (1980) (332)
- Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry. (1989) (283)
- Preferential cutaneous infiltration by neoplastic thymus-derived lymphocytes. Morphologic and functional studies. (1974) (228)
- Central nervous system complications in patients with diffuse histiocytic and undifferentiated lymphoma: leukemia revisited. (1976) (228)
- The use of nicotinamide to modify the toxicity of streptozotocin diabetes without loss of antitumor activity. (1967) (212)
- Immunosuppressive and cytotoxic chemotherapy: long-term complications. (1975) (196)
- The use of drugs in combination for the treatment of cancer: rationale and results. (1973) (191)
- A comparison of combination chemotherapy and combined modality therapy for locally advanced gastric carcinoma (1982) (189)
- Prevention of chronic doxorubicin cardiotoxicity in beagles by liposomal encapsulation. (1983) (180)
- Gastrointestinal toxicity of chemotherapeutic agents. (2006) (174)
- Liposomal protection of adriamycin-induced cardiotoxicity in mice. (1980) (171)
- Potential for prolonged disease-free survival following combination chemotherapy of non-Hodgkin's lymphoma. (1974) (162)
- Streptozotocin: depression of mouse liver pyridine nucleotides. (1968) (157)
- Islet cell tumors: current concepts and management. (1973) (140)
- A randomized trial comparing adjuvant fluorouracil, doxorubicin, and mitomycin with no treatment in operable gastric cancer. International Collaborative Cancer Group. (1990) (138)
- Carcinoma-associated hemolytic-uremic syndrome: a complication of mitomycin C chemotherapy. (1985) (132)
- Combination chemotherapy for advanced breast cancer: response and effect on survival. (1976) (130)
- 5‐Fluorouracil, adriamycin, and mitomycin‐C (FAM) chemotherapy for advanced adenocarcinoma of the pancreas (1980) (124)
- Tetracycline and quinacrine in the control of malignant pleural effusions. A randomized trial (1978) (119)
- 5-Fluorouracil, mitomycin, and doxorubicin (FAM) in carcinoma of the biliary tract. (1984) (115)
- Pancreatic Islet Cell Tumors Produced by the Combined Action of Streptozotocin and Nicotinamide 1 (1971) (111)
- A putative role for nicotinamide adenine dinucleotide-promoted nuclear protein modification in the antitumor activity of N-methyl-N-nitrosourea. (1977) (111)
- Pharmacological, toxicological, and therapeutic evaluation in mice of doxorubicin entrapped in cardiolipin liposomes. (1985) (105)
- Cachexia of malignancy. Potential role of insulin in nutritional management (1979) (104)
- Carcinoembryonic antigen: its role as a marker in the management of cancer. A National Institutes of Health Consensus Development Conference. (1981) (103)
- Cyclical Combination Chemotherapy for Advanced Breast Carcinoma (1974) (102)
- Maintenance chemotherapy for advanced Hodgkin's disease in remission. (1973) (100)
- Phase II trial of streptozotocin, mitomycin‐C and 5‐fluorouracil (SMF) in the treatment of advanced pancreatic cancer (1978) (99)
- Ovarian carcinoma metastatic to the diaphragm--frequently undiagnosed at laparotomy. A preliminary report. (1973) (96)
- Randomized phase II clinical trial of adriamycin, methotrexate, and actinomycin‐d in advanced measurable pancreatic carcinoma. A gastrointestinal tumor study group report (1978) (95)
- Cutaneous seeding of pancreatic cancer by skinny-needle aspiration biopsy. (1980) (93)
- Doxorubicin-induced chronic cardiotoxicity and its protection by liposomal administration. (1982) (86)
- Streptozotocin for malignant insulinomas and carcinoid tumor. Report of eight cases and review of the literature. (1973) (86)
- Successful management of the Sézary syndrome. Mobilization and removal of extravascular neoplastic T cells by leukapheresis. (1974) (85)
- Microangiopathic hemolytic anemia, thrombocytopenia, and renal failure in patients treated for adenocarcinoma (1981) (84)
- Pancreatic cholera: benefical effects of treatment with streptozotocin. (1975) (84)
- Elevated DNA topoisomerase II activity in nitrogen mustard-resistant human cells. (1987) (83)
- A structure-activity analysis of chemical and biological parameters of chloroethylnitrosoureas in mice. (1977) (81)
- Therapeutic use of tamoxifen in advanced breast cancer: correlation with biochemical parameters. (1976) (78)
- Mechanisms of sensitivity and resistance of murine tumors to 5-fluorouracil. (1980) (78)
- Effects of streptozotocin on carbohydrate and lipid metabolism in the rat. (1971) (76)
- Peritoneoscopy: a valuable staging tool in ovarian carcinoma. (1975) (73)
- Panel: cancer of the pancreas. (1978) (71)
- 5-fluorouracil, adriamycin, and mitomycin in the treatment of adenocarcinoma of unknown primary. (1986) (70)
- Probable clonal origin of acute myeloblastic leukemia following radiation and chemotherapy of colon cancer. (1978) (67)
- Animal toxicology for early clinical trials with anticancer agents. (1981) (66)
- Treatment of cancer-associated hemolytic uremic syndrome with staphylococcal protein A immunoperfusion. (1986) (64)
- Nitrosourea interaction with chromatin and effect on poly(adenosine diphosphate ribose) polymerase activity. (1979) (64)
- Initial clinical trials with methyl‐ccnu 1‐(2‐chloroethyl)‐3‐(4‐methyl cyclohexyl)‐1‐nitrosourea (meccnu) (1973) (64)
- Tumor 5-fluorodeoxyuridylate concentration as a determinant of 5-fluorouracil response. (1978) (60)
- Amifostine‐mediated protection of normal bone marrow from cytotoxic chemotherapy (1993) (59)
- Chemotherapy of the blastic phase of chronic granulocytic leukemia: hypodiploidy and response to therapy. (1976) (58)
- Nutritional complications of cancer and its treatment. (1975) (57)
- Phase II study of trimetrexate, fluorouracil, and leucovorin for advanced colorectal cancer. (1997) (57)
- CEA (carcinoembryonic antigen): Its role as a marker in the management of cancer (2004) (56)
- Cytotoxicity of estramustine, a steroid-nitrogen mustard derivative, through non-DNA targets. (1983) (53)
- Gastric carcinoma and thrombotic thrombocytopenic purpura: association with plasma immune complex concentrations. (1982) (50)
- Renal tumorigenic action of streptozotocin (NSC-85998) in rats. (1968) (50)
- Non‐Hodgkin's lymphoma: Patterns of relapse from complete remission after combination chemotherapy (1975) (48)
- Medical Oncology: Basic Principles and Clinical Management of Cancer (1993) (47)
- Cutaneous T‐cell lymphoma (1976) (47)
- Binding of chlorozotocin and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea to chromatin and nucleosomal fractions of HeLa cells. (1978) (46)
- Chemotherapy of advanced ovarian carcinoma: a prospective randomized comparison of phenylalanine mustard and high dose cyclophosphamide. (1974) (46)
- Efficacy of tetrahydrocannabinol in patients refractory to standard antiemetic therapy (1988) (42)
- Plasma Glucose Levels in Normal and Adrenalectomized Mice Treated with Streptozotocin and Nicotinamide (1968) (41)
- The toxicity of Escherichia coli L-asparaginase. (1969) (40)
- Chemotherapy of pancreatic carcinoma (1984) (39)
- Phase I clinical trial of spirogermanium. (1980) (37)
- Modification of Renal Tumorigenic Effect of Streptozotocin by Nicotinamide: Spontaneous Reversibility of Streptozotocin Diabetes 1 (1976) (37)
- Chemotherapy of pancreatic carcinoma (1981) (36)
- Biological and biochemical properties of 1-(2-chloroethyl)-3-(beta-D-glucopyranosyl)-1-nitrosourea (NSC D 254157), a nitrosourea with reduced bone marrow toxicity. (1977) (35)
- 5-Fluorouracil (5-FU), methyl-CCNU, and vincristine in the treatment of advanced colorectal cancer: phase II study utilizing weekly 5-FU. (1976) (34)
- Barriers to Efficient Development of Cancer Therapeutics (2006) (34)
- Structure-activity studies of methylnitrosourea antitumor agents with reduced murine bone marrow toxicity. (1977) (33)
- Minimal activity of recombinant clone a interferon in metastatic colon cancer. (1984) (33)
- Sensitivity of human and murine hematopoietic precursor cells to 2-[3-(2-chloroethyl)-3-nitrosoureido]-D-glucopyranose and 1,3-bis(2-chloroethyl)-1-nitrosourea. (1978) (33)
- Therapy of advanced lymphocytic lymphoma a preliminary report of a randomized trial between combination chemotherapy (CVP) and intensive radiotherapy. (1975) (32)
- 5‐fluorouracil, adriamycin, and mitomycin‐C (FAM) chemotherapy for adenocarcinoma of the lung (1979) (32)
- A structure--activity study of seven new water soluble nitrosoureas. (1979) (32)
- Chemotherapeutic management of the hormone‐secreting endocrine malignancies (1972) (32)
- Hexamethylmelamine as a single second‐line agent in ovarian cancer (1990) (32)
- Chemotherapy of pancreatic cancer. (1979) (31)
- Phase I studies on chlorozotocin (1978) (29)
- Antitumor and toxicity evaluation of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes (2004) (27)
- A comparison of the biological and biochemical properties of 1-(4-amino-2-methylpyrimidin-5-yl)methyl-3-(2-chloroethyl)-3-nitrosourea and 2-[3-(2-chloroethyl)-3-nitrosoureido]-D-glucopyranose. (1978) (26)
- Mutagenic activity of nitrosourea antitumor agents. (1980) (26)
- Chlorozotocin. Mechanism of reduced bone marrow toxicity in mice. (1979) (26)
- Chemotherapeutic Alteration of Small Intestinal Morphology and Function: A Progress Report (1979) (26)
- Streptozotocin Diabetes in Monkeys and Dogs, and Its Prevention by Nicotinamide (1973) (25)
- Enhanced antitumor effect of cytosine arabinoside given in a schedule dictated by kinetic studies in vivo. (1973) (25)
- Current diagnosis and management of pancreatic carcinoma. (1976) (24)
- The role of chemotherapy in the management of gastric and pancreatic carcinomas. (1985) (24)
- Effect of carbamoylation on the repair of nitrosourea-induced DNA alkylation damage in L1210 cells. (1979) (24)
- Gastrointestinal involvement in the Sézary syndrome. (1977) (24)
- Current management of advanced and locally unresectable gastric carcinoma. (1982) (23)
- A controlled trial of the effect of 4-hydroxypyrazolopyrimidine (allopurinol) on the toxicity of a single bolus dose of 5-fluorouracil. (1985) (23)
- Percutaneous liver biopsy, peritoneoscopy and laparotomy: an assessment of relative merits in the lymphomata. (1975) (23)
- Cisplatin in patients with gastric cancer: a Cancer and Leukemia Group B phase II study. (1986) (23)
- Chemotherapy of large intestinal carcinoma. Current results and future prospects (1975) (23)
- Potential of liposomes to ameliorate anthracycline-induced cardiotoxicity. (1984) (23)
- Clinical pharmacology of daunorubicin in phase I patients with solid tumors: development of an analytical methodology for daunorubicin and its metabolites. (1984) (22)
- Unexplained increase in serum creatine kinase isoenzyme MB activity in a lung cancer patient. (1981) (22)
- Overview on the Management of Adrenocortical Carcinoma (ACC) (1983) (21)
- Use of amifostine in bone marrow purging. (1996) (21)
- The case for a new national program for the development of cancer therapeutics. (2001) (21)
- Differentiation of carcinomatous and bacterial meningitis (1972) (21)
- Phase-II trial of tamoxifen in advanced breast cancer (2004) (20)
- Phase II trials of 5-FU, doxorubicin, and cisplatin in advanced, measurable adenocarcinoma of the lung and stomach. (1986) (19)
- Randomized clinical trial of mitomycin-C with or without pretreatment with WR-2721 in patients with advanced colorectal cancer (2004) (19)
- 1-Methyl-1-nitrosourea Depression of Brain Nicotinamide Adenine Dinucleotide in the Production of Neurologic Toxicity (1969) (19)
- Preclinical evaluation of WR-151327: an orally active chemotherapy protector. (1994) (19)
- Sorbent removal of adriamycin in vitro and in vivo. (1979) (19)
- Elevated topoisomerase II activity and altered chromatin in nitrogen mustard-resistant human cells. (1987) (19)
- Comparative pharmacology of pentamethylmelamine and hexamethylmelamine in mice. (1980) (19)
- Osteoblastic bone metastasis in Zollinger-Ellison syndrome. (1976) (19)
- Preclinical toxicology of anticancer agents. (1977) (18)
- Will hemoperfusion be useful for cancer chemotherapeutic drug removal? (1980) (18)
- Hepatotoxicity of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea. (CCNU) in dogs: the use of serial percutaneous liver biopsies. (1973) (18)
- Phase II study of sequential methotrexate-5-FU therapy in advanced measurable colorectal cancer. (1982) (18)
- Correlation of nitrosourea murine bone marrow toxicity with deoxyribonucleic acid alkylation and chromatin binding sites. (1982) (17)
- Biology, diagnosis, and chemotherapeutic management of pancreatic malignancy. (1977) (17)
- Management of gastrointestinal cancer. (1977) (17)
- Pharmacology of chlorozotocin Nsc-178248), a new nitrosourea antitumor agent. (1976) (16)
- New protective agents for bone marrow in cancer therapy. (1991) (16)
- Influence of hydrocortisone on the binding of nitrosoureas to nuclear chromatin subfractions. (1980) (16)
- Fast neutron irradiation for locally advanced pancreatic cancer. (1981) (15)
- Phase-II trial of tamoxifen in advanced breat cancer. (1979) (15)
- The cyclophosphamide, hexamethylmelamine, 5 fluorouracil (CHF) regimen in the treatment of advanced and recurrent ovarian cancer. (1985) (15)
- Cellular pharmacology of mu-[1,2-bis(diphenylphosphino)ethane]bis[(1-thio-beta-D-gluco pyranosato-S)gold(I)]: a novel antitumor agent. (1986) (14)
- Results of combination chemotherapy of non-Hodgkin's lymphoma. (1975) (14)
- Alkylating agent interactions with the nuclear matrix. (1983) (14)
- Nephrotoxicity of cis-diamminedichloroplatinum(II) as measured by urinary beta-glucuronidase. (1980) (14)
- Fractionation of mammalian bone marrow by counterflow centrifugation‐elutriation using a continuous albumin gradient: analysis of granulocyte‐macrophage colony‐forming units (1982) (13)
- Contributions of nitrosoureas to cancer treatment. (1986) (13)
- Phase II trial of 5-fluorouracil, adriamycin, and mitomycin C in advanced colorectal cancer. (1978) (13)
- 1-methyl-1-nitrosourea and dialkylnitrosamine depression of nicotinamide adenine dinucleotide. (1969) (13)
- Structures of the decomposition products of chlorozotocin: new intramolecular carbamates of 2-amino-2-deoxyhexoses (1981) (13)
- Clinical experiences with extracorporeal immunoperfusion of plasma from cancer patients. (1984) (12)
- Pharmacology of Nitrosourea Antitumor Agents1 (1978) (12)
- Biological and biochemical properties of the 2-hydroxyl metabolites of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea. (1978) (12)
- Laetrile toxicity: a report of two cases. (1977) (12)
- Combination chemotherapy for locally advanced pancreatic cancer: equivalence to external beam irradiation and implication for future management. (1983) (12)
- Hemolytic--uremic syndrome in an adult: light and electron microscopic observations. (1970) (11)
- Phase II study of 5-FU, doxorubicin, and mitomycin (FAM) and chlorozotocin in advanced measureable pancreatic cancer. (1982) (11)
- High-dose intermittent intravenous infusion of procarbazine (NSC-77213). (1973) (11)
- Unique sensitivity of nitrogen mustard-resistant human Burkitt lymphoma cells to novobiocin. (1988) (11)
- COMPUTERISED AXIAL TOMOGRAPHY FOR DIAGNOSIS OF PANCREATIC CANCER (1976) (11)
- Repair of DNA alkylation induced in L1210 leukemia and murine bone marrow by three chloroethylnitrosoureas. (1982) (11)
- A phase II study of chlorozotocin in metastatic malignant melanoma (1980) (10)
- The potential for clinical application of in vitro assays predicting 5-FU sensitivity in man. (1981) (10)
- Organic thiophosphate WR-151327 suppresses expression of HIV in chronically infected cells. (1994) (10)
- A phenol technique for extraction of alkylated DNA, RNA, and protein from a single tissue sample. (1977) (10)
- Use of peritoneoscopy for initial staging and posttherapy evaluation of patients with ovarian carcinoma. (1975) (10)
- Cellular and molecular mechanisms of the bone marrow sparing effects of the glucose chloroethylnitrosourea chlorozotocin. (1984) (9)
- 6-[Bis(2-chloroethyl)amino]-6-deoxygalactopyranose hydrochloride (C6-galactose mustard), a new alkylating agent with reduced bone marrow toxicity. (1987) (9)
- Aspartato(1,2-cyclohexanediamine)platinum(II) complexes : synthesis and characterization; effects of minor impurities on antitumor activity (1991) (9)
- Hepatic estrogen and progesterone receptors in an estrogen-associated hepatic neoplasm (2004) (9)
- Treatment of advanced breast cancer with two doxorubicin‐containing regimens (1984) (9)
- Therapy of gastrointestinal cancer. (1985) (8)
- Lupus vulgaris and Hodgkin's disease. (1972) (8)
- Antitumor activity and bone marrow toxicity of aminoglucose mustard anticancer agents in mice. (1986) (8)
- Chemotherapy and combined modality therapy for locally advanced and metastatic gastric carcinoma. (1985) (8)
- Pulmonary disease as a complication of chlorozotocin chemotherapy. (1981) (8)
- Streptozotocin Treatment of Streptozotocin-lnduced Islet Cell Adenomas in Rats 1 (1976) (7)
- Pharmacology of nitrosourea antitumor agents. (1978) (7)
- Pharmacological disposition of 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl)-1-nitrosourea in mice. (1984) (7)
- Letter: Meningeal involvement in lymphoma. (1974) (7)
- CAMP (cyclophosphamide, doxorubicin, methotrexate, and procarbazine) for epidermoid and large cell anaplastic carcinoma of the lung. (1981) (7)
- CORRELATION WITH EXTENT OF DEPRESSION OF PANCREATIC ISLET NICOTINAMIDE ADENINE DINUCLEOTIDE (1974) (6)
- A Phase I trial of spirogermanium administered on a continuous infusion schedule (2004) (6)
- Mitomycin C: Experience in the United States, with emphasis on gastric cancer (2004) (6)
- Comparison of the experimental antitumor activities of three nitrosourea derivatives chlorozotocin, RFCNU and CNCC encapsulated in liposomes with those in the free state. (1985) (6)
- Phase II studies of methyl glyoxal bis‐guanylhydrazone (NSC 32946) in carcinoma of the colon and lung (1982) (6)
- Prednimustine: the rationale for clinical development. (1986) (6)
- Recent results of clinical therapeutic trials for gastrointestinal malignancies conducted in the United States. (1981) (6)
- Carcinoid carcinomatous meningitis. (1985) (6)
- Nutrition and cancer: Prospects for clinical research (1980) (6)
- WR-2721: a chemotherapy and radiation-protective agent. (1990) (6)
- Therapy of Advanced Gastric Carcinoma: The Georgetown‐Lombardi Cancer Center Experience (1989) (5)
- Selective inhibition of cardiac cyclic nucleotide phosphodiesterases by doxorubicin and daunorubicin. (1985) (5)
- Phase II study of chlorozotocin in leukemia and other hematologic malignancies. (1981) (5)
- A phase I study of daunorubicin in advanced untreatable malignancies. (1984) (5)
- Enhancement of nitrosourea cytotoxicity in vitro using hydrocortisone. (1982) (5)
- Laetrile toxicity: a report of two patients. (1978) (5)
- Phase I trial and clinical pharmacology of 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl)-1-nitrosourea. (1981) (5)
- Biochemical and pharmacologic properties of nitrosoureas. (1981) (5)
- Decision making in oncology (1989) (4)
- Molecular pharmacology of nitrosoureas. (1981) (4)
- Renal cell carcinoma causing a selective mineralocorticoid insufficiency. (1982) (4)
- Studies on mechanisms of 5-fluorouracil resistance in murine and human tumors. (1979) (4)
- Management of Hepatic Metastases: A General Overview (1984) (4)
- Analysis of prognostic factors and survival in patients with ovarian cancer treated with second-line hexamethylmelamine (altretamine). (1991) (4)
- Recognition of hepatitis B surface antigen by the human hepatoma cell line HepG2. (1986) (4)
- 500 Amifostine (AMI) selectively protects against cumulative toxicities of cyclophosphamide (C) and cisplatin (P) (1995) (4)
- Pharmacologic disposition of chlorozotocin in mice. (1978) (4)
- Toxicity evaluation of doxorubicin entrapped in cardiolipin liposomes in mice. Abstr. (1983) (3)
- Chapter 31 – STREPTOZOTOCIN (1981) (3)
- New sugar mitomycin C analogues: preparation, murine P388 antitumor activity, and leukopenia induction. (1990) (3)
- Study of nitrosourea glycosyl analogs--V. An oriented phase II trial of RFCNU. (1982) (3)
- Biochemical correlates of 5-FU chemotherapy in murine colonic tumors (1977) (3)
- 6-bis-(2-chloroethyl)amino-6-deoxy-D-galactopyranose hydrochloride: synthesis, chemical characterization, murine P388 antitumor activity, and bone marrow toxicity. (1989) (3)
- Phase II trial of spirogermanium in breast adenocarcinoma: a Cancer and Leukemia Group B Study. (1982) (3)
- The effect of sequential addition of the nitrosourea, chlorozotocin, to the FAM combination in advanced gastric cancer (1983) (3)
- Beagle dog as predictor of schedule-dependent toxicity of 5-fluoro-2-deoxyuridine. (1972) (3)
- 179 Promotion of multilineage hematopoiesis in patients with myelodysplastic syndrome: A phase I/II clinical trial with amifostine (1997) (3)
- 577 Amifostine reduces cumulative cisplatin nephrotoxicity (1995) (3)
- Ongoing trials in the surgical adjuvant management of colorectal cancer. (1978) (3)
- The role of hexamethylmelamine in the management of ovarian cancer. (1991) (3)
- Correlation of nitrosourea bone marrow toxicity with dna alkylation and chromatin binding sites. Abstr. (1980) (3)
- Phase II trial of mitoxantrone in advanced colorectal cancer. (1982) (3)
- Presidential address: the plight of clinical cancer research. (1984) (3)
- Phase II study of daunorubicin in previously untreated patients with advanced colorectal carcinoma. (1985) (2)
- Protection of chronic cardiotoxicity of adriamycin by liposomal delivery. Abstr. (1981) (2)
- Depression of mouse nicotinamide adenine dinucleotide by n-methyl-n- -nitrosourea and dialkylnitrosamines. Abstr. (1968) (2)
- Overview of Childhood Pancreatic Tumors (1982) (2)
- Phase II study of PCNU in colorectal carcinoma. (1981) (2)
- Protection against streptozotocin induced diabetes. Abstr. (1967) (2)
- Differential binding of chlorozotocin (clz) and ccnu to murine bone marrow chromatin. Abstr. (1979) (2)
- The role of the FDA in the national cancer program: friend or foe? (2003) (2)
- Phase I study of oral spirogermanium (1990) (2)
- Phase II trial of PCNU in advanced renal cell carcinoma and malignant melanoma. (1984) (2)
- Murine anti-tumor activity of new water soluble platinum(II) complexes with reduced toxicity. (1990) (2)
- Pharmacology of Nitrosourea Anticancer Agents (1984) (2)
- A Case of Metastatic Insulinoma in an Adolescent Girl (1982) (2)
- Synthesis and Characterization of a Series of Water Soluble Amidomalonato-(lR,2R-Cyclohexanediamine)Platinum(II) Complexes (1990) (2)
- WR-2721 (Ethyol®): Reduction in Toxicity of Anticancer Therapy without Loss of Efficacy (1991) (2)
- Phase-II study of cis-diammine-dichloro platinum (cis-platinum), bleomycin and methotrexate for advanced squamous cell carcinoma of head and neck (2004) (2)
- Chlorozotocin (clz) binding to chromatin. A possible mechanism for reduced murine myelotoxicity. Abstr. (1978) (2)
- How much toxicity is necessary? (1984) (2)
- Enhanced nitrosourea cytotoxicity in cell culture by sodium butyrate. (1985) (2)
- The FAM regimen for gastric cancer: a progress report. (1981) (1)
- Chemoprotective Effects of Amifostine on Hematopoietic and Nonhematopoietic Tissue (1995) (1)
- The role of carbamoylation in nitrosourea toxicity and antitumor activity in mice. Abstr. (1976) (1)
- Effect of carbamoylation on repair of nitrosourea (nu) alkyalted dna in l1210 cells. Abstr. (1978) (1)
- DNA repeat length in chromatin from murine bone marrow and L1210 leukaemia cells. (1985) (1)
- Estramustine: historical background and preclinical trials. (1983) (1)
- Repair of chloroethylnitrosourea-induced dna lesions in murine bone marrow and l1210 cells. Abstr. (1981) (1)
- Peritoneoscopy a valuable tool for the initial staging and 2nd look in ovarian carcinoma (1974) (1)
- Amifostine — protection from hematotoxicity and nephrotoxicity induced by chemotherapy (1995) (1)
- Pharmacological, lexicological, and Therapeutic Evaluation in Mice of Doxorubicin Entrapped in Cardiolipin Liposomes1 (2006) (1)
- Streptozotocin : Depression of Mouse Liver Pyridine Nucleotides ' PhilipS (1)
- Hexamethylmelamine (HMM) for advanced ovarian cancer (1989) (1)
- A phase II study of chlorozotocin in advanced large bowel carcinoma: A cooperative study between two institutions (1984) (1)
- Importance of phospholipids to nitrosourea interactions with the nuclear envelope and associated nucleic acids. (1983) (1)
- Chemotherapy of colorectal carcinoma. (1976) (1)
- Pharmacologic and Therapeutic Characteristics of Anthracycline Liposome Preparation (1982) (1)
- Prediction of clinical response to 5-fluorouracil-containing chemotherapy: preliminary results of in vitro assay in human breast cancer. (1980) (1)
- Nitrosoureas in cancer treatment : proceedings of the International Symposium on Nitrosoureas in Cancer Treatment held in Montpellier, France, 26-27 January 1981 (1981) (1)
- Chemotherapy for advanced gastric carcinoma. (1986) (1)
- The place of tamoxifen in the treatment of breast cancer. (1980) (1)
- Chlorozotocin (clz). Mechanism of reduced myelotoxicity for mice. Abstr. (1977) (1)
- Synthesis and Murzne P388 Antitumor Activity of Uridine Mustard: A Preliminary Report (1990) (1)
- Antitumor and pharmacologic disposition studies of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes. Abstr. (1983) (1)
- Clinical strategies in the chemotherapy of gastrointestinal cancer. (1980) (1)
- CNCC, a new nitrosourea cysteamine analogue. I: Experimental study (1984) (1)
- A randomized comparison of two chemotherapy regimes: BACOP vs COPP in the treatment of diffuse histiocytic and mixed lymphoma (1985) (0)
- Chemotherapy of gastric cancer. (1988) (0)
- The malignant lymphomas: current concepts of diagnosis and management. (1980) (0)
- Antitumor Activity and Bone Marrow Toxicity of Aminoglucose Mustard Anticancer Agents in Mice 1 (2006) (0)
- Pharmacokinetic and metabolic studies of chlorozotocin in mice. Abstr. (1977) (0)
- Paul Calabresi, MD. (2006) (0)
- Letter: Hypercalcemia and streptozotocin. In comment. (1974) (0)
- FAM (5-fluorouracil, doxorubicin, and mitomycin) plus triazinate (FAM-T) in gastric carcinoma: a combined phase II trial of the Mid-Atlantic Oncology Program and the Pan American Health Organization. (1987) (0)
- Letter: Carcinoid syndrome. (1976) (0)
- Chemotherapy in advanced ovarian cancer. (1973) (0)
- Letter: Combination chemotherapy for breast cancer. (1975) (0)
- Improving the toxicity curves in chemotherapy. (1988) (0)
- Structure-Activity Studies of Methylnitrosourea Antitumor Agents with Reduced Murine Bone Marrow Toxicity 1 (2006) (0)
- Seminars in oncology. Introduction. (1976) (0)
- Biological and Biochemical Properties of the 2-Hydroxyl Metabolites of 1-( 2-Chloroethy l )-3-cyclohexy 1-1-nitrosourea 1 (2006) (0)
- DNA repeatlength inchromatin frommurine bonemarrow andL1210leukaemia cells (1985) (0)
- 7 – CLINICAL PRESENTATIONS OF GASTROINTESTINAL CANCER (1981) (0)
- SEPTEMBER 1973 3-( Tetraacetyl Glucopyranos-2-yl )-1-( 2-chloroethyl ) 4-nitrosourea , an Antitumor Agent with Modified Bone Marrow Toxicity (0)
- A Phase I trial o f sp irogermanium administered on a cont inuous in fus ion schedule (0)
- The in vitro sensitivity of human and murine hemopoietic precursor cells to chlorozotocin (CLZ) and 1 3 bis (2 chloroethyl) 1 nitrosourea (BCNU) (1977) (0)
- Mitomycin C: experience in the United States, with emphasis on gastric cancer. (1978) (0)
- Chemotherapy of gastric carcinoma. (1987) (0)
- Inhibition of cyclic nucleotides phosphodiesterase in mouse tissues by doxorubicin (dx) and daunomycin (dnr). Abstr. (1983) (0)
- The Toxicity of Escherichia coli L-Asparaginase1 (2006) (0)
- Pharmacologic disposition of 1-(2-chloroethyl)-3-(2,6-dioxo-1- -piperidyl)-1-nitrosourea (pcnu) in mice. Abstr. (1980) (0)
- 748 Trimetrexate (TMTX) modulation of 5-fluorouracil/leucovorin (5-FU/LV) for advanced colorectal cancer (1995) (0)
- The current state of chemotherapy in gastric cancer. (1986) (0)
- Experimental Models and their Predictive Value in New Drug Development: A Critical Appraisal: I. Toxicity Models. (1984) (0)
- Cellular and Molecular Mechanisms of the Bone Marrow Sparing Effects of the Glucose (2005) (0)
- Chemotherapy of Pancreatic, Colorectal and Gastric Cancer (1981) (0)
- Chemotherapy of Non-Hodgkin's Lymphoma Potential for Prolonged Disease-free Survival Following Combination (2011) (0)
- Current concepts in the drug treatment of cancer. (1978) (0)
- Mustard gas derivatives of c-6 aminogalaktose and their use. (1985) (0)
- Oncolipids? A possible new approach to diagnosis of cancer. (1986) (0)
- DNA Alkylation Damage in L1210 cells Effect of Carbamoylation on the Repair of Nitrosourea-induced (2013) (0)
- A comparison of the relative murine bone marrow toxicities of 1,3,4,6-tetra-0-acetyl-2-(di-2-chloroehyl)amino-2-deoxy-d- -glucopyranose (tgm) and nitrogen mustard (hn2). Abstr. (1981) (0)
- Preclinical and clinical studies on chlorozotocin, a new nitrosourea with decreased bone marrow toxicity. (1980) (0)
- Anthracyklinglycosid-preparations, their use and preparation (1982) (0)
- Aspartato(1,2-cyclohexanediamine)platinum(II) Complexes: Synthesis and Characterization; Effects of Minor Impurities on Antitumor Activity. (1991) (0)
- Nitroso urea interactions with the nuclear envelope nuclear matrix and associated chromatin (1981) (0)
- [Therapeutic progress in digestive system neoplasms. VII. Treatment of pancreatic neoplasms]. (1980) (0)
- A trial of cisplatin (P) and cyclophosphamide (C) ± WR-2721 (WR) in advanced ovarian carcinoma (1992) (0)
- Alkylation of template-active chromatin in murine bone marrow (mbm) and p388 leukemia cells by chlorozotocin (clz) and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (ccnu). Abstr. (1982) (0)
- Studies on the mechanism of tumor resistance to chloroethylnitrosoureas (cenus). Abstr. (1983) (0)
- Endocrine tumors. (1987) (0)
- Experimental studies with glibenclamide in the rat. (1970) (0)
- Mechanisms and management of malnutrition states in patients with cancer. (1976) (0)
- 1-(2-CHLOROETHYL)-3-(4-METHYL CYCL0HEXYL)-1- (1972) (0)
- Medical Oncology: Medical Aspects of Malignant Disease (1975) (0)
- The effect of hydrocortisone on chromatin alkylation by chlorozotocin (1978) (0)
- Recent Advances in Cancer and Radiotherapeutics: Clinical Oncology (1973) (0)
- This desk reference on cancer. (1978) (0)
- Anthracyklinglycosid-kardiolipinkompleks encapsulated in liposomes, processes for their preparation and therapeutic composition containing this (1982) (0)
- Structure-Activity Studies of Methylnitrosourea Antitumor Agents with Reduced Murine Bone Marrow Toxicity1 (2006) (0)
- [Phase II study of 3 new nitrosoureas, 1 American (chlorozotocin) and 2 French (RFCNU and RPCNU)]. (1982) (0)
- Receptor-Mediated Endocytosis by Normal and Proliferating Hepatocytes and Liposomal Drug Delivery (1984) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Philips S. Schein?
Philips S. Schein is affiliated with the following schools:
